Sbir phase II topic 84 entitled "antiviral drugs to cure chronic hepatitis B virus infection"

Ended Definitive Contract Awarded Last action

Contract number
75N93022C00042
Awardee
Awarding agency
Obligated
$1,549,999

Award facts

Contract value 100% obligated
$1,549,998.81 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
No set-aside
Competition
Full and Open Competition · 1 offer Negotiated Proposal / Quote
Pricing
Cost Plus Fixed Fee
Place of performance
Germantown, MD, USA
Legislative mandates

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Change Order P00002 $50,000
Other Administrative Action P00001 $0
Original award $1,499,999

About this award

The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $1.55 million definitive cost plus fixed fee contract to Hbvtech of Germantown, Maryland to perform work under Small Business Innovation Research Phase II Topic 84, entitled "Antiviral Drugs to Cure Chronic Hepatitis B Virus Infection." The contract period of performance spans from September 1, 2022 through August 25, 2025. Under this award, Hbvtech will develop antiviral drugs to cure chronic Hepatitis B virus infections.

Quick answers

Who was awarded contract 75N93022C00042?

75N93022C00042 was awarded to Hbvtech, L.l.c by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 1, 2022.

How much is contract 75N93022C00042 worth?

The government has obligated $1,549,999 on 75N93022C00042.

Was contract 75N93022C00042 competed?

The extent of competition for 75N93022C00042 was full and open competition. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award